{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:12:30Z","timestamp":1778274750875,"version":"3.51.4"},"reference-count":258,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201141","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:04:03Z","timestamp":1769735043000},"page":"201141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-9279","authenticated-orcid":false,"given":"Alexander W.","family":"Rankin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolla F.","family":"Abu-Arja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica S.","family":"Thakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemalatha G.","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201141_bib2","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"M\u00f6ricke","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib5","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib6","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.19.02892","article-title":"Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131","volume":"38","author":"Salzer","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.20.00494","article-title":"Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932","volume":"39","author":"Angiolillo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cncr.23220","article-title":"Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93\/98 and the adult trials AMLCG 92\/99 and AMLSG HD93\/98A","volume":"112","author":"Creutzig","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib10","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3\/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29281","article-title":"Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group","volume":"68","author":"Elgarten","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001","volume":"68","author":"Burns","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib13","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib14","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pbc.22612","article-title":"Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study","volume":"55","author":"Gorman","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib16","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.seminhematol.2016.01.003","article-title":"Autologous stem cell transplantation versus alternative allogeneic donor transplants in adult acute leukemias","volume":"53","author":"Claude Gorin","year":"2016","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.omton.2026.201141_bib18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020009342","article-title":"A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation","volume":"137","author":"Qayed","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib19","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12030599","article-title":"Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions","volume":"12","author":"Moritz","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2026.201141_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103348","article-title":"Measurable residual disease in hematologic malignancies: a biomarker in search of a standard","volume":"86","author":"Chandhok","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.omton.2026.201141_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201141_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41409-024-02197-3","article-title":"Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP\/EBMT study","volume":"59","author":"Sharma","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib24","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission","volume":"123","author":"Weisdorf","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib26","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib27","doi-asserted-by":"crossref","first-page":"38.e1","DOI":"10.1016\/j.jtct.2022.09.003","article-title":"Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study","volume":"29","author":"Meur","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201141_bib28","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.12639","article-title":"Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?","volume":"164","author":"Balduzzi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib30","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib31","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib33","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib34","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS","volume":"31","author":"Radford","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201141_bib35","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","article-title":"Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival","volume":"20","author":"Koreth","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib36","first-page":"801","article-title":"Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia","volume":"88","author":"Barrios","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2014.12.029","article-title":"Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies","volume":"21","author":"Horn","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","article-title":"Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia","volume":"39","author":"Huisman","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.imbio.2013.10.008","article-title":"CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT","volume":"219","author":"Steger","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.omton.2026.201141_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1700778","article-title":"Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation","volume":"19","author":"Dermime","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3324\/haematol.2009.013920","article-title":"Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia","volume":"95","author":"Craddock","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00277-017-3204-6","article-title":"Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia","volume":"97","author":"Yang","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.omton.2026.201141_bib44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.bbmt.2020.07.037","article-title":"Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide","volume":"26","author":"DeZern","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib46","first-page":"975","article-title":"Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation","volume":"18","author":"Porter","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib47","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1704321","article-title":"Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children","volume":"33","author":"Gorczy\u00f1ska","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib49","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bmt.1704444","article-title":"Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective","volume":"33","author":"Bader","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib50","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/blood-2011-04-348805","article-title":"Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation","volume":"118","author":"Rettinger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bmt.1702726","article-title":"Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease","volume":"27","author":"de Lima","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib52","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib53","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib54","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-0012.2012.01626.x","article-title":"Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study","volume":"26","author":"Wang","year":"2012","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/bmt.2011.15","article-title":"Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study","volume":"47","author":"Schmid","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib56","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib57","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2012-12-470872","article-title":"HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion","volume":"122","author":"Stevanovic","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib58","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib59","doi-asserted-by":"crossref","first-page":"330.e1","DOI":"10.1016\/j.jtct.2023.02.009","article-title":"Efficacy of Azacitidine and Prophylactic Donor Lymphocyte Infusion after HSCT in Pediatric Patients with Acute Myelogenous Leukemia: A Retrospective Pre-Post Study","volume":"29","author":"Booth","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201141_bib60","doi-asserted-by":"crossref","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.omton.2026.201141_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/08880018.2020.1829220","article-title":"Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia","volume":"38","author":"Huschart","year":"2021","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib62","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood.2022015959","article-title":"KIR-favorable TCR-\u03b1\u03b2\/CD19-depleted haploidentical HCT in children with ALL\/AML\/MDS: primary analysis of the PTCTC ONC1401 trial","volume":"140","author":"Pulsipher","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imlet.2013.09.027","article-title":"Negative depletion of \u03b1\/\u03b2+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation","volume":"155","author":"Locatelli","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.omton.2026.201141_bib64","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib65","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib66","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib67","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1200\/JCO.2024.42.16_suppl.6518","article-title":"Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia","volume":"42","author":"Pan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib68","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib69","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib70","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201141_bib71","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12967-022-03797-7","article-title":"Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML)","volume":"20","author":"Lu","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201141_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib73","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2023-180387","article-title":"A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed\/Refractory Acute Myeloid Leukemia in Adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib74","doi-asserted-by":"crossref","first-page":"TPS6586","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6586","article-title":"A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed\/refractory acute myeloid leukemia (AMpLify)","volume":"42","author":"Daver","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib75","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201141_bib76","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib78","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1182\/blood-2023-180990","article-title":"Phase 1\/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib79","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.jtct.2023.12.293","article-title":"Trial in Progress: Phase 1\/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation","volume":"30","author":"Shah","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.omton.2026.201141_bib80","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib81","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.17751","article-title":"Adoptive immunotherapy with double-bright (CD56(bright)\/CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study","volume":"195","author":"Silla","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","article-title":"A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia","volume":"7","author":"Nguyen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201141_bib84","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib85","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40164-022-00353-3","article-title":"Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia","volume":"11","author":"Zhou","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib86","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib87","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201141_bib88","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051592","article-title":"Transgenic HA-1-Specific CD8(+) T-Lymphocytes Selectively Target Leukemic Cells","volume":"15","author":"Pilunov","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201141_bib90","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2141.2002.03536.x","article-title":"Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion","volume":"117","author":"Kircher","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib91","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3324\/haematol.2011.053371","article-title":"Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study","volume":"97","author":"Meij","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib92","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2019.03.027","article-title":"Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms","volume":"25","author":"Narayan","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib93","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cncr.26190","article-title":"AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group","volume":"118","author":"Cooper","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib94","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib95","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib96","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2017-01-762336","article-title":"Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531","volume":"130","author":"Guest","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib97","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3324\/haematol.2018.191841","article-title":"Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-M\u00fcnster study group","volume":"104","author":"Niktoreh","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib98","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.clml.2020.07.001","article-title":"Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation","volume":"20","author":"Genthon","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.omton.2026.201141_bib99","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/blood.V120.21.1970.1970","article-title":"Gemtuzumab Ozogamicin After Allogeneic Stem Cell Transplantation for Acute Leukemia","volume":"120","author":"Kobayashi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib100","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1182\/blood.V110.11.4380.4380","article-title":"Gemtuzumab Ozogamicin as Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML)","volume":"110","author":"Cascavilla","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib101","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41409-024-02311-5","article-title":"Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies","volume":"59","author":"Kaito","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib102","doi-asserted-by":"crossref","first-page":"12973","DOI":"10.1182\/blood-2022-165289","volume":"140","author":"Cooper","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib103","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib104","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134576","article-title":"Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia","volume":"136","author":"Aldoss","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib105","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1182\/blood-2022-158029","article-title":"Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed\/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial","volume":"140","author":"Lamble","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib106","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib107","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","article-title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","volume":"8","author":"Lane","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2022-162842","article-title":"Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-\u03b1 (FR-\u03b1)-Targeting ADC in Relapsed\/Refractory CBF2AT3-GLIS2 AML","volume":"140","author":"Meshinchi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib109","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/1538-7445.AM2022-1075","article-title":"Abstract 1075: Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001 - folate receptor alpha-directed C\u2019Dot-drug-conjugate","volume":"82","author":"Le","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201141_bib110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib111","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bmt.2009.266","article-title":"5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis","volume":"45","author":"Czibere","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib112","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib113","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib114","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib115","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib116","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib117","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201141_bib118","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4110\/in.2012.12.2.58","article-title":"Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy","volume":"12","author":"Kwon","year":"2012","journal-title":"Immune Netw."},{"key":"10.1016\/j.omton.2026.201141_bib119","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib120","first-page":"1766","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201141_bib121","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib122","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2013.64","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib123","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"S\u00e1nchez-Abarca","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib124","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.hemonc.2021.03.001","article-title":"Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia","volume":"16","author":"Keruakous","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.omton.2026.201141_bib125","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.clml.2024.01.012","article-title":"Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"24","author":"Pasvolsky","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.omton.2026.201141_bib126","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/s41409-019-0677-z","article-title":"Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia","volume":"55","author":"Ma","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib127","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib128","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1080\/10428194.2018.1443334","article-title":"Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies","volume":"59","author":"Maples","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omton.2026.201141_bib129","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.13248","article-title":"Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia","volume":"169","author":"Oshikawa","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib130","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood-2023-191115","article-title":"Decitabine Combined with Low-Dose Chemotherapy Is Effective in the Treatment of Pediatric Refractory\/Relapsed Acute Myeloid Leukemia","volume":"142","author":"Fan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib131","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2019-131062","article-title":"Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study","volume":"134","author":"Saucier","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib132","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ajh.26510","article-title":"Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed\/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium","volume":"97","author":"Pommert","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2026.201141_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030496","article-title":"Nivolumab Plus 5-Azacitidine in Pediatric Relapsed\/Refractory Acute Myeloid Leukemia (AML): Phase I\/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201141_bib134","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial","volume":"38","author":"Gao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib135","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27284","article-title":"Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia","volume":"65","author":"Tamura","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib136","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201141_bib137","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201141_bib138","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib139","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib140","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/bloodadvances.2023012041","article-title":"Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?","volume":"8","author":"Masetti","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib141","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15071983","article-title":"Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience","volume":"15","author":"Trabal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201141_bib142","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib143","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib144","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2021005164","article-title":"Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia","volume":"5","author":"McCall","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib145","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib146","article-title":"The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow","volume":"13","author":"Lange","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201141_bib147","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201141_bib148","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.bbmt.2019.04.018","article-title":"Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"25","author":"Xuan","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib149","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib150","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib151","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib152","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib153","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2018-99-113582","article-title":"Radius: A Phase 2 Randomized Trial Investigating Standard of Care \u00b1 Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML","volume":"132","author":"Maziarz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib154","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2024-207763","article-title":"Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML","volume":"144","author":"Oran","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib155","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib156","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/cncr.30680","article-title":"Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia","volume":"123","author":"Battipaglia","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib157","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pbc.25437","article-title":"Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3\/ITD acute myeloid leukemia","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib158","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1182\/blood.V122.21.3969.3969","article-title":"Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3\/ITD+ AML","volume":"122","author":"Pollard","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib159","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1615\/CritRevOncog.2014012393","article-title":"Modulation of immune responses by histone deacetylase inhibitors","volume":"20","author":"Schotterl","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.omton.2026.201141_bib161","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib162","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201141_bib163","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201141_bib164","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib165","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201141_bib166","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/leu.2011.142","article-title":"Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups","volume":"25","author":"Damm","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib167","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201141_bib168","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib169","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1182\/blood-2023-189036","article-title":"Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant","volume":"142","author":"Zucenka","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib170","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1182\/bloodadvances.2024015527","article-title":"Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia","volume":"9","author":"Okeleji","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib171","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.13019","article-title":"Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells","volume":"107","author":"Fukushima","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2026.201141_bib172","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/bloodadvances.2020001991","article-title":"Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse","volume":"4","author":"Kent","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib173","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201141_bib174","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib176","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib177","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201141_bib178","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbmt.2020.01.021","article-title":"Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation","volume":"26","author":"Wang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib179","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201141_bib180","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib181","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/bloodadvances.2022008403","article-title":"Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Godfrey","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib182","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26464","article-title":"Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia","volume":"64","author":"Horn","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib184","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/tri.13601","article-title":"Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations","volume":"33","author":"Lawitschka","year":"2020","journal-title":"Transpl. Int."},{"key":"10.1016\/j.omton.2026.201141_bib185","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib186","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.exphem.2005.06.034","article-title":"Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia","volume":"33","author":"Nijmeijer","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omton.2026.201141_bib187","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1182\/blood-2023-182639","article-title":"Risk-Adapted Donor Lymphocyte Infusion after Hematopoietic Cell Transplant in Pediatric and Young Adult Patients Is Associated with Low Risk of Graft Versus Host Disease","volume":"142","author":"Suryaprakash","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib188","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112699","article-title":"Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia","volume":"13","author":"Tsirigotis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201141_bib189","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41409-020-0798-4","volume":"55","author":"Kothari","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib191","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2008.135","article-title":"Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population","volume":"42","author":"Levine","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib192","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27950","article-title":"Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia","volume":"66","author":"Liberio","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib193","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2016.10.006","article-title":"Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation","volume":"23","author":"Rettinger","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib194","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2024-207902","article-title":"Efficacy and Safety of Donor Lymphocyte Infusion after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients","volume":"144","author":"Gruhn","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib196","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib197","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.29141","article-title":"Phase 1\/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Shimoni","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2016.12.201","article-title":"Post-Allogeneic Stem Cell Transplantation Maintenance Dasatinib in Philadelphia Chromosome Positive Acute Leukemia","volume":"23","author":"Maher","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib199","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00277-021-04504-0","article-title":"The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study","volume":"100","author":"Leotta","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.omton.2026.201141_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106930","article-title":"Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation","volume":"121","author":"Chen","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2026.201141_bib201","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.bbmt.2019.09.022","article-title":"Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review","volume":"26","author":"Warraich","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib202","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/cncr.35232","article-title":"Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study","volume":"130","author":"Guan","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib204","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201141_bib205","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.2019004685","article-title":"Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL","volume":"136","author":"Saini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib206","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib207","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib208","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib209","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12185-022-03329-5","article-title":"Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group","volume":"116","author":"Kodama","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omton.2026.201141_bib210","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome\u2013like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib211","article-title":"Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients","volume":"6","author":"Shumock","year":"2023","journal-title":"Cancer Rep."},{"key":"10.1016\/j.omton.2026.201141_bib212","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1080\/10428194.2019.1605510","article-title":"Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1","volume":"60","author":"Aldoss","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omton.2026.201141_bib213","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib214","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/bloodadvances.2018025726","article-title":"Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib215","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL","volume":"42","author":"Hodder","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib216","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201141_bib217","first-page":"234","article-title":"Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen","volume":"110","author":"Peters","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib218","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib219","first-page":"3111","article-title":"Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation","volume":"11","author":"Wu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omton.2026.201141_bib220","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41409-022-01846-9","article-title":"Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC","volume":"58","author":"Chauvet","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib221","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1182\/blood-2018-99-109998","article-title":"Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review","volume":"132","author":"Durer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib222","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2023-191047","article-title":"A Phase IB\/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance","volume":"142","author":"Webster","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib223","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2024-210268","article-title":"Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia","volume":"144","author":"Ji","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib224","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib225","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.bbmt.2019.12.606","article-title":"Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia","volume":"26","author":"Kebriaei","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib226","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-024-01092-w","article-title":"Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia\/lymphoma following allogeneic hematopoietic cell transplantation","volume":"14","author":"Huang","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201141_bib227","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070051","volume":"13","author":"Sakaguchi","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.omton.2026.201141_bib228","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","article-title":"A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia","volume":"8","author":"Metheny","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib229","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.750218","article-title":"Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse","volume":"11","author":"Ding","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib231","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"127","author":"Jacoby","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib232","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41409-018-0403-2","article-title":"A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"54","author":"Hu","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib233","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood.2025028790","article-title":"Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion","volume":"146","author":"Roddie","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib234","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41375-024-02251-5","article-title":"Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"38","author":"Lu","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib235","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib236","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201141_bib237","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201141_bib238","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201141_bib239","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201141_bib240","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2021014648","article-title":"Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL","volume":"139","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib241","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41409-023-01948-y","article-title":"Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia","volume":"58","author":"Fan","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib242","article-title":"Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib243","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib244","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s44228-022-00019-1","article-title":"Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia","volume":"5","author":"Hassan","year":"2023","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.omton.2026.201141_bib245","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib246","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbmt.2013.04.010","article-title":"Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival","volume":"19","author":"Forcade","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201141_bib247","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib248","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201141_bib249","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2021.279851","article-title":"Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study","volume":"107","author":"Cerrano","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib250","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201141_bib251","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201141_bib252","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1182\/blood.V99.12.4610","article-title":"Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma","volume":"99","author":"Bellucci","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib253","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","article-title":"Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion","volume":"123","author":"Bachireddy","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib254","first-page":"2293","article-title":"Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment","volume":"110","author":"Vel\u00e1zquez","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201141_bib255","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib256","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41375-023-01849-5","article-title":"The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial","volume":"37","author":"Lee","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib257","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201141_bib258","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201141_bib259","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:27:30Z","timestamp":1778272050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":258,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000172"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201141","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201141"}}